Maiden Biosciences

Form 483 issued November 28, 2022 · Gaithersburg, Maryland

Inspection
Nov 21 – Nov 28, 2022
Investigator
Jude C. Dike
Observations
2
Pages
5
FEI number
3012973796

In short: On November 28, 2022, FDA issued a Form 483 with 2 observations to Maiden Biosciences in Gaithersburg, Maryland (FEI 3012973796) after an inspection that ran Nov 21 – Nov 28, 2022. The investigator was Jude C. Dike. Most observations concern management controls; the most-cited regulation is 21 CFR 820.20 (management responsibility).

At a glance

2 of 2 observations on this 483 concern management controls.

Management controls2

Most cited: 21 CFR 820.20(b)(3) (1×) · 820.25(b) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01

    No management representative had been appointed to ensure that quality system requirements are met, and to…

  2. 02

    Procedures for training and identifying training needs…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Maiden Biosciences?

FDA listed 2 observations on this Form 483, mostly about management controls. The most-cited regulation is 21 CFR 820.20 (management responsibility). The opening words of each observation are shown on this page.

Who inspected Maiden Biosciences?

Jude C. Dike is named on this Form 483, for the inspection of Nov 21 – Nov 28, 2022. Each investigator has a profile showing what they cite most.

When was Maiden Biosciences inspected by FDA?

The inspection ran Nov 21 – Nov 28, 2022, and the Form 483 is dated November 28, 2022.

How do I get the full Form 483 for Maiden Biosciences?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free